Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Ranbaxy Wins Case, Signs For Two Deals
June 4, 2007
| A version of this story appeared in
Volume 85, Issue 23
A court in Oslo, Norway, ruled last week that four of Pfizer's patents covering Lipitor are either invalid or not infringed by a proposed generic atorvastatin product made by India's Ranbaxy Laboratories. The ruling clears the way for Ranbaxy to market its generic version of the world's leading anticholesterol statin in Norway. Pfizer says it will appeal the ruling. Meanwhile, Ranbaxy has acquired U.S. rights to 13 dermatological drugs from Bristol-Myers Squibb. And the company has taken a 15% stake in Indian peptide drugmaker Jupiter Bioscience.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter